Neovascular Glaucoma Clinical Trial
Official title:
Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study
The STRONG Study is a phase II/III prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre study of aganirsen antisense oligonucleotide, a topical treatment for iCRVO intended to prevent Neovascular Glaucoma (NVG). The study will evaluate the efficacy of two different doses of aganirsen formulated in an eye emulsion in avoiding new vessel formation by blocking the Insulin Receptor Substrate (IRS)-1. Eligible patients will be treated with aganirsen or placebo for a period of 24 weeks. They will also be invited to participate in sub-studies working on the analysis of gonioscopic images, detection of biomarkers for neovascular glaucoma and risk factors for ischaemic central retinal vein occlusion. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00491712 -
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection
|
N/A | |
Recruiting |
NCT04519619 -
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
|
||
Completed |
NCT01370135 -
Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
|
N/A | |
Completed |
NCT04970251 -
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
|
N/A | |
Completed |
NCT02805257 -
Ahmed Glaucoma Valve Surgery With Mitomycin-C
|
Phase 2 | |
Recruiting |
NCT02067013 -
Analysis of Aqueous and Vitreous Humor
|
Phase 2 | |
Completed |
NCT00524758 -
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
|
Phase 3 | |
Withdrawn |
NCT00727038 -
Lucentis for New Onset Neovascular Glaucoma
|
Phase 1/Phase 2 | |
Completed |
NCT01711879 -
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
|
N/A | |
Terminated |
NCT02260219 -
Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
|
N/A | |
Withdrawn |
NCT00441181 -
Effects of Travoprost on Neovascular Glaucoma
|
N/A | |
Completed |
NCT01051583 -
Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
|
Phase 2 | |
Completed |
NCT05156021 -
A Study on the Treatment Strategy of NVG Secondary to PDR
|
N/A | |
Terminated |
NCT01301378 -
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
|
N/A | |
Not yet recruiting |
NCT05316142 -
Any Unique Identifier Assigned to the Protocol by the Sponsor
|
N/A | |
Recruiting |
NCT04844619 -
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
|
Phase 1 | |
Completed |
NCT03154892 -
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
|
N/A |